Skip to main content
SpringerLink
Log in

Thyroid Cancer and the Endocrinologist

  • Chapter
Practical Management of Thyroid Cancer

  • 821 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418–428.

    Article  PubMed  CAS  Google Scholar 

  2. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338:297–306.

    Article  PubMed  CAS  Google Scholar 

  3. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer; results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998; 8:737–744.

    PubMed  CAS  Google Scholar 

  4. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999; 9:421–427.

    PubMed  CAS  Google Scholar 

  5. Hardy KJ, Walker BR, Lindsay RS, et al. Thyroid cancer management. Clin Endocrinol 1995; 42:651–655.

    CAS  Google Scholar 

  6. Vanderpump MPJ, Alexander L, Scarpello JHB, et al. An audit of the management of thyroid cancer in a district general hospital. Clin Endocrinol 1998; 48:419–424.

    Article  CAS  Google Scholar 

  7. Kumar H, Daykin J, Holder R, et al. An audit of management of differentiated thyroid cancer in specialist and non-specialist clinic settings. Clin Endocrinol 2001; 54:719–723.

    Article  CAS  Google Scholar 

  8. Kendall-Taylor P. Thyroid cancer in the UK: can we do it better? Clin Endocrinol 2001; 54:705–706.

    Article  CAS  Google Scholar 

  9. Hamming JF, Goslings BM, van Steenis GJ, et al. The value of fine-needle aspiration biopsy in patients with nodular thyroid disease divided into groups of suspicion of malignant neoplasm on clinical grounds. Arch Intern Med 1990; 150:113.

    Article  PubMed  CAS  Google Scholar 

  10. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89:163–168.

    Article  PubMed  CAS  Google Scholar 

  11. Vierhapper H, Raber W, Bieglmayer C, et al. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 1997; 89:1589–1593.

    Article  Google Scholar 

  12. Eng C. Familial papillary thyroid cancer — many syndromes, too many genes? J Clin Endocrinol Metab 2000; 85:1755–1757

    Article  PubMed  CAS  Google Scholar 

  13. Pal T, Vogl FD, Chappuis PO, et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 2001; 85:5307–5312.

    Article  Google Scholar 

  14. Belfiore A, Russo D, Vigneri R, Filetti S. Graves’ disease, thyroid nodules and thyroid cancer. Clin Endocrinol 2001; 55:711–718.

    Article  CAS  Google Scholar 

  15. Kossev P, Livolsi V. Lymphoid lesions of the thyroid: review in light of the revised European-American lymphoma classification and upcoming World Health Organization classification. Thyroid 1999; 9:1273–1280.

    PubMed  CAS  Google Scholar 

  16. Wiersinga WM. Is repeated fine-needle aspiration cytology indicated in (benign) thyroid nodules? Eur J Endocrinol 1995; 132:661–662.

    PubMed  CAS  Google Scholar 

  17. Danese D, Seiaochitano S, Farsetti A, Andreoli M, Pontecorvi A. Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. Thyroid 1998; 8:15–21.

    Article  PubMed  CAS  Google Scholar 

  18. Kunreuther E, Orcutt J, Benson CB, et al. The predictive value of FNAC from the dominant (largest) nodule thyroid nodule in a multinodular goiter (abstract). Thyroid 2004; 14:760.

    Google Scholar 

  19. Ito Y, Urono T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003; 13:381–387.

    Article  PubMed  Google Scholar 

  20. Brierly JD, Panzarella T, Tsang RW, Gospodarowicz MK, O’Sullivan B. A comparison of different staging systems’ predictability of patient outcome: thyroid carcinoma as an example. Cancer 1997; 79:2414–2423.

    Article  Google Scholar 

  21. D’Avanzo A, Ituarte P, Treseler P, et al. Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid 2004; 14:453–458.

    Article  PubMed  CAS  Google Scholar 

  22. Mazzaferri E. A randomized trial of remnant ablation — in search of an impossible dream? J Clin Endocrinol Metab 2004; 89:3662–3664.

    Article  PubMed  CAS  Google Scholar 

  23. Serhal DI, Nasrallah MP, Arafah BM. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89:3285–3289.

    Article  PubMed  CAS  Google Scholar 

  24. Morris LF, Wilder MS, Waxman AD, Braunstein GD. Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma. Thyroid 2001; 11:749–755.

    Article  PubMed  CAS  Google Scholar 

  25. Pluymen MJHM, Eustatia-Rutten C, Goslings BM, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol 2003; 58:428–435.

    Article  Google Scholar 

  26. Park II JT, Hennessey JV. Two-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rhTSH scanning in patient taking levothyroxine. Thyroid 2004; 14:57–63.

    Article  PubMed  CAS  Google Scholar 

  27. Mazzaferri EL. Gonadal damage from 131I therapy for thyroid cancer. Clin Endocrinol 2002; 57:313–314.

    Article  Google Scholar 

  28. Vini L, Hyer S, Al-Sandi A, Pratt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J 2002; 78:92–93.

    Article  PubMed  CAS  Google Scholar 

  29. Ceccarelli C, Bencivelli W, Morciano D, Pinchera A, Pacini F. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab 2001; 86:3512–3515.

    Article  PubMed  CAS  Google Scholar 

  30. Hyer S, Vini L, O’Connell M, Pratt B, Harmer C. Testicular dose and fertility in men following I131 therapy for thyroid cancer. Clin Endocrinol 2002; 56:755–758.

    Article  CAS  Google Scholar 

  31. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003; 349:1517–1525.

    Article  PubMed  CAS  Google Scholar 

  32. Pujol P, Daures J-P, Nsakala N, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81:4318–4323.

    Article  PubMed  CAS  Google Scholar 

  33. Böhm J, Kosma V-M, Eskelinen M, et al. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma. Eur J Endocrinol 1999; 141:460–467.

    Article  PubMed  Google Scholar 

  34. Wang P-W, Wang S-T, Liu R-T, et al. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84:4549–4553.

    Article  PubMed  CAS  Google Scholar 

  35. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249–1252.

    Article  PubMed  CAS  Google Scholar 

  36. Fazio S, Palmieri EA, Lombardi G, Biondi B. Effect of thyroid hormone on the cardiovascular system. Recent Prog Horm Rev 2004; 59:31–50.

    Article  CAS  Google Scholar 

  37. Gullus S, Altuntas F, Dinzer I, Erol C, Kamel N. Effect of TSH-suppressive therapy on cardiac morphology and function: beneficial effects of the addition of b-blockade on cardiac function. Eur J Endocrinol 2004; 150:655–661.

    Article  Google Scholar 

  38. Toivonen J, Tähtelä R, Laitinen K, Risteli J, Välimäki MJ. Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol 1998; 138:667–673.

    Article  PubMed  CAS  Google Scholar 

  39. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994; 130:350–356.

    Article  PubMed  CAS  Google Scholar 

  40. Uzzan B, Campos J, Cucherat M, et al. Effect on bone mass of long-term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996; 81:4278–4289.

    Article  PubMed  CAS  Google Scholar 

  41. Surks MI, Ortin E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291:228–238.

    Article  PubMed  CAS  Google Scholar 

  42. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004; 150:105–112.

    Article  PubMed  CAS  Google Scholar 

  43. Kitamura Y, Shimazu K, Nagahama M, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 1999; 84:4043–4049.

    Article  PubMed  CAS  Google Scholar 

  44. Levy EG. Cost of care. Thyroid 2000; 10:1119–1121.

    Article  PubMed  CAS  Google Scholar 

  45. Mendoza A, Shaffer B, Karakla D, et al. Quality-of-life with well-differentiated thyroid cancer: treatment toxicities and their reduction. Thyroid 2004; 14:133–140.

    Article  PubMed  CAS  Google Scholar 

  46. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997; 7:613–619.

    PubMed  CAS  Google Scholar 

  47. Cohen O, Dabhi S, Karasik A, Zwas SZ. Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH. Eur J Endocrinol 2004; 150:285–290.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

    Wilmar M. Wiersinga MD, PhD

Authors
  1. Wilmar M. Wiersinga MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Ohio State University, Columbus, OH, USA

    Ernest L. Mazzaferri MD, MACP (Emeritus Professor) (Emeritus Professor)

  2. University of Florida, Gainsville, FL, USA

    Ernest L. Mazzaferri MD, MACP (Emeritus Professor) (Emeritus Professor)

  3. Department of Radiotherapy, Royal Marsden Hospital, London, UK

    Clive Harmer FRCR, FRCP (Head of Thyroid Unit) (Head of Thyroid Unit)

  4. Northern Centre for Cancer Treatment, Newcastle upon Tyne, UK

    Ujjal K. Mallick MS, FRCR (Vice-Chair) (Vice-Chair)

  5. Thyroid Cancer Subgroup, National Cancer Research Institute, UK

    Ujjal K. Mallick MS, FRCR (Vice-Chair) (Vice-Chair)

  6. Northern Cancer Network Thyroid Cancer Group, UK

    Ujjal K. Mallick MS, FRCR (Vice-Chair) (Vice-Chair)

  7. Department of Medicine, University of Newcastle upon Tyne, UK

    Pat Kendall-Taylor MD, FRCP (Emeritus Professor) (Emeritus Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag London Limited

About this chapter

Cite this chapter

Wiersinga, W.M. (2006). Thyroid Cancer and the Endocrinologist. In: Mazzaferri, E.L., Harmer, C., Mallick, U.K., Kendall-Taylor, P. (eds) Practical Management of Thyroid Cancer. Springer, London. https://doi.org/10.1007/1-84628-013-3_10

Download citation

  • DOI: https://doi.org/10.1007/1-84628-013-3_10

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-910-4

  • Online ISBN: 978-1-84628-013-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation